Search

Acute rheumatic fever and rheumatic heart disease: Incidence and progression in the Northern Territory of Australia 1997 to 2010

The reduction in ARF recurrence indicates that the RHD control program has improved secondary prophylaxis; a decline in RHD incidence is expected to follow.

Updated model of group A Streptococcus M proteins based on a comprehensive worldwide study

Group A Streptococcus (GAS) M protein is an important virulence factor and potential vaccine antigen, and constitutes the basis for strain typing (emm-typing).

Group A streptococcal vaccines: Paving a path for accelerated development

Vaccine prevention of GAS infections and their immunological complications has been a goal of researchers for decades.

Professor Jonathan Carapetis AM

Head, Strep A Translation; Co-Founder of REACH

Acute Rheumatic Fever Diagnosis Collaborative Network (ARC)

ARC is a global network of collaborators committed to reducing the burden of RHD in our lifetime.

Australian Strep A Vaccine Initiative (ASAVI)

The Australian Strep A Vaccine Initiative (ASAVI) is an Australian-led global initiative with the goal of reducing the disease burden caused by Group A Streptococcus (Strep A) infection through effective vaccination.

BPG Formulation Preferences Study: Exploring patient, family and clinician reformulations preferences for BPG

The key objective of this study is to collect data about patient and clinician preferences about reformulations.

Burden of rheumatic heart disease (RHD) and impact of prevention strategies: comprehensive evidence to drive the RHD Endgame

This project will use a multi-jurisdictional linked RHD dataset to establish a baseline burden of RHD in Australia to allow for monitoring the impact of burden over time, and to form the basis of clearly defined targets for the END RHD CRE Endgame Strategy.

Defining target penicillin concentrations for subsequent studies of a reformulated long-acting benzathine penicillin prototype

Aims: To determine the minimum inhibitory concentrations of penicillin G against a representative collection of Strep A strains; and to evaluate the impact of penicillin G concentration and size of bacterial inoculum on the prophylactic effect for Strep A strains

Development of a longer acting formulation of Penicillin G for the treatment and prevention of acute rheumatic fever and rheumatic heart disease

This project aims to develop a longer acting formulation of penicillin, such that frequency of the injection can be increased up to 3-6 months.